| Bioactivity | (Rac)-Zevaquenabant ((Rac)-MRI-1867, compound 6b) is a cannabinoid receptor type 1 (CB1R)/iNOS antagonist, with a Ki of 5.7 nM for CB1R. (Rac)-Zevaquenabant is potential for the research of liver fibrosis[1]. | ||||||||||||
| Target | CB1R/iNOS | ||||||||||||
| Name | (Rac)-Zevaquenabant | ||||||||||||
| CAS | 1610420-28-4 | ||||||||||||
| Formula | C25H21ClF3N5O2S | ||||||||||||
| Molar Mass | 547.98 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Design, Synthesis, and Biological Evaluation of Novel, Non-Brain-Penetrant, Hybrid Cannabinoid CB 1 R Inverse Agonist/Inducible Nitric Oxide Synthase (iNOS) Inhibitors for the Treatment of Liver Fibrosis. |
(Rac)-Zevaquenabant
CAS: 1610420-28-4 F: C25H21ClF3N5O2S W: 547.98
(Rac)-Zevaquenabant ((Rac)-MRI-1867, compound 6b) is a cannabinoid receptor type 1 (CB1R)/iNOS antagonist, with a Ki of
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.